These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
104 related items for PubMed ID: 18068388
21. A fusion product of the complete Borrelia burgdorferi outer surface protein A (OspA) and the hepatitis B virus capsid protein is highly immunogenic and induces protective immunity similar to that seen with an effective lipidated OspA vaccine formula. Nassal M, Skamel C, Kratz PA, Wallich R, Stehle T, Simon MM. Eur J Immunol; 2005 Feb; 35(2):655-65. PubMed ID: 15668917 [Abstract] [Full Text] [Related]
22. Serum reactivity against Borrelia burgdorferi OspA in patients with rheumatoid arthritis. Hsieh YF, Liu HW, Hsu TC, Wei JC, Shih CM, Krause PJ, Tsay GJ. Clin Vaccine Immunol; 2007 Nov; 14(11):1437-41. PubMed ID: 17881508 [Abstract] [Full Text] [Related]
23. Development of a multiplex assay for the detection of antibodies to Borrelia burgdorferi in horses and its validation using Bayesian and conventional statistical methods. Wagner B, Freer H, Rollins A, Erb HN, Lu Z, Gröhn Y. Vet Immunol Immunopathol; 2011 Dec 15; 144(3-4):374-81. PubMed ID: 21890217 [Abstract] [Full Text] [Related]
24. Transcriptional regulation of the ospAB and ospC promoters from Borrelia burgdorferi. Alverson J, Bundle SF, Sohaskey CD, Lybecker MC, Samuels DS. Mol Microbiol; 2003 Jun 15; 48(6):1665-77. PubMed ID: 12791146 [Abstract] [Full Text] [Related]
25. A systemic approach to identify non-abundant immunogenic proteins in Lyme disease pathogens. Yaş OB, Coleman AS, Lipman RM, Sharma K, Raghunandanan S, Alanazi F, Rana VS, Kitsou C, Yang X, Pal U. mSystems; 2024 Jan 23; 9(1):e0108723. PubMed ID: 38078774 [Abstract] [Full Text] [Related]
26. Protective efficacy of an oral vaccine to reduce carriage of Borrelia burgdorferi (strain N40) in mouse and tick reservoirs. Scheckelhoff MR, Telford SR, Hu LT. Vaccine; 2006 Mar 10; 24(11):1949-57. PubMed ID: 16300863 [Abstract] [Full Text] [Related]
27. A reverse transcriptase-polymerase chain reaction assay of Borrelia burgdorferi 16S rRNA for highly sensitive quantification of pathogen load in a vector. Ornstein K, Barbour AG. Vector Borne Zoonotic Dis; 2006 Mar 10; 6(1):103-12. PubMed ID: 16584333 [Abstract] [Full Text] [Related]
28. Infection of mice with lyme disease spirochetes constitutively producing outer surface proteins a and B. Strother KO, Hodzic E, Barthold SW, de Silva AM. Infect Immun; 2007 Jun 10; 75(6):2786-94. PubMed ID: 17371860 [Abstract] [Full Text] [Related]
29. Borrelia burgdorferi mutant lacking Osp: biological and immunological characterization. Sadziene A, Thomas DD, Barbour AG. Infect Immun; 1995 Apr 10; 63(4):1573-80. PubMed ID: 7890424 [Abstract] [Full Text] [Related]
30. Two regulatory elements required for enhancing ospA expression in Borrelia burgdorferi grown in vitro but repressing its expression during mammalian infection. Xu Q, McShan K, Liang FT. Microbiology (Reading); 2010 Jul 10; 156(Pt 7):2194-2204. PubMed ID: 20395273 [Abstract] [Full Text] [Related]
31. Presence of common antigenic epitope in outer surface protein (Osp) A and OspB of Japanese isolates identified as Borrelia garinii. Masuzawa T, Kaneda K, Suzuki H, Wang J, Yamada K, Kawabata H, Johnson RC, Yanagihara Y. Microbiol Immunol; 1996 Jul 10; 40(6):455-8. PubMed ID: 8839432 [Abstract] [Full Text] [Related]
32. Structure-based design of a second-generation Lyme disease vaccine based on a C-terminal fragment of Borrelia burgdorferi OspA. Koide S, Yang X, Huang X, Dunn JJ, Luft BJ. J Mol Biol; 2005 Jul 08; 350(2):290-9. PubMed ID: 15935380 [Abstract] [Full Text] [Related]
33. Sequence of the complete osp operon encoding two major outer membrane proteins of a European Borrelia burgdorferi isolate (B29). Fellinger W, Redl B, Stöffler G. Gene; 1992 Oct 12; 120(1):127-8. PubMed ID: 1398118 [Abstract] [Full Text] [Related]
34. Essential role for OspA/B in the life cycle of the Lyme disease spirochete. Yang XF, Pal U, Alani SM, Fikrig E, Norgard MV. J Exp Med; 2004 Mar 01; 199(5):641-8. PubMed ID: 14981112 [Abstract] [Full Text] [Related]
35. Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial. Wressnigg N, Pöllabauer EM, Aichinger G, Portsmouth D, Löw-Baselli A, Fritsch S, Livey I, Crowe BA, Schwendinger M, Brühl P, Pilz A, Dvorak T, Singer J, Firth C, Luft B, Schmitt B, Zeitlinger M, Müller M, Kollaritsch H, Paulke-Korinek M, Esen M, Kremsner PG, Ehrlich HJ, Barrett PN. Lancet Infect Dis; 2013 Aug 01; 13(8):680-9. PubMed ID: 23665341 [Abstract] [Full Text] [Related]
36. Regulation of expression of major outer surface proteins in Borrelia burgdorferi. Margolis N, Rosa PA. Infect Immun; 1993 May 01; 61(5):2207-10. PubMed ID: 8478112 [Abstract] [Full Text] [Related]
37. The outer surface lipoprotein OspA of Borrelia burgdorferi provides co-stimulatory signals to normal human peripheral CD4+ and CD8+ T lymphocytes. Knigge H, Simon MM, Meuer SC, Kramer MD, Wallich R. Eur J Immunol; 1996 Oct 01; 26(10):2299-303. PubMed ID: 8898937 [Abstract] [Full Text] [Related]
38. Functional heterogeneity in the antibodies produced to Borrelia burgdorferi. Benach JL. Wien Klin Wochenschr; 1999 Dec 10; 111(22-23):985-9. PubMed ID: 10666815 [Abstract] [Full Text] [Related]
39. Protective immunization with plasmid DNA containing the outer surface lipoprotein A gene of Borrelia burgdorferi is independent of an eukaryotic promoter. Simon MM, Gern L, Hauser P, Zhong W, Nielsen PJ, Kramer MD, Brenner C, Wallich R. Eur J Immunol; 1996 Dec 10; 26(12):2831-40. PubMed ID: 8977275 [Abstract] [Full Text] [Related]
40. Antigenic and genetic heterogeneity of Borrelia burgdorferi populations transmitted by ticks. Ohnishi J, Piesman J, de Silva AM. Proc Natl Acad Sci U S A; 2001 Jan 16; 98(2):670-5. PubMed ID: 11209063 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]